

CERTIFICATE OF ANALYSIS HUMAN CELL LINE PROTEIN

Human CA15-3

Code No. Grade	P301-4 Low Cross Contamination	
Lot No.		
	N	
RECEIVER INFORMATION Expiry Date	(5 years from manufacturing date)	
Manufacturing Date	(5 years from manufacturing date)	
Storage Temperature	Store below -15°C.	
Storage Notes	Avoid freeze thaw cycles.	
Shipping Notes	Dry Ice recommended.	
	_	
PRODUCT INFORMATION		
Source	Human carcinoma cell line.	
Presentation	Single homogenous batch, 0.2µm filtered	supplied frozen in a
resentation	0.05M sodium phosphate buffer, pH 7.5 c	
	and 0.09% NaN ₃ .	
	, i i i i i i i i i i i i i i i i i i i	
HEALTH AND SAFETY		
Application	For Research and Manufacturing Only.	
	For Research and Manufacturing Only.	
Application	For Research and Manufacturing Only.	
		Result
Application	Starting material tested using FDA	Result
Application	Starting material tested using FDA approved tests for:	Result
Application	Starting material tested using FDA approved tests for: HIV 1 & 2 antibodies	Result
Application	Starting material tested using FDA approved tests for: HIV 1 & 2 antibodies Hepatitis B Surface Antigen	Result
Application	Starting material tested using FDA approved tests for: HIV 1 & 2 antibodies	Result
Application	Starting material tested using FDA approved tests for:HIV 1 & 2 antibodiesHepatitis B Surface AntigenHepatitis C virus antibodies	Result
Application	Starting material tested using FDA approved tests for: HIV 1 & 2 antibodies Hepatitis B Surface Antigen Hepatitis C virus antibodies HIV 1 / HBV / HCV NAT	Result
Application Infectious Disease Tests	Starting material tested using FDA approved tests for: HIV 1 & 2 antibodies Hepatitis B Surface Antigen Hepatitis C virus antibodies HIV 1 / HBV / HCV NAT Syphilis (RPR)	
Application	Starting material tested using FDA approved tests for:HIV 1 & 2 antibodiesHepatitis B Surface AntigenHepatitis C virus antibodiesHIV 1 / HBV / HCV NATSyphilis (RPR)No test can guarantee the absence of an	
Application Infectious Disease Tests	Starting material tested using FDA approved tests for: HIV 1 & 2 antibodies Hepatitis B Surface Antigen Hepatitis C virus antibodies HIV 1 / HBV / HCV NAT Syphilis (RPR)	
Application Infectious Disease Tests Precaution	Starting material tested using FDA approved tests for:HIV 1 & 2 antibodiesHepatitis B Surface AntigenHepatitis C virus antibodiesHIV 1 / HBV / HCV NATSyphilis (RPR)No test can guarantee the absence of an handle as potentially hazardous.	infectious agent. Please
Application Infectious Disease Tests	Starting material tested using FDA approved tests for:HIV 1 & 2 antibodiesHepatitis B Surface AntigenHepatitis C virus antibodiesHIV 1 / HBV / HCV NATSyphilis (RPR)No test can guarantee the absence of an handle as potentially hazardous.For further information and technical deta	infectious agent. Please
Application Infectious Disease Tests Precaution	Starting material tested using FDA approved tests for:HIV 1 & 2 antibodiesHepatitis B Surface AntigenHepatitis C virus antibodiesHIV 1 / HBV / HCV NATSyphilis (RPR)No test can guarantee the absence of an handle as potentially hazardous.	infectious agent. Please

Part of **BBI Group**



ANALYSIS

TEOTO		
TESTS	SPECIFICATIONS	RESULTS
Determination Method		
CA15-3 concentration by Roche Modular	> 10 Ku/ml	Ku/ml
CA125 concentration as determined by Roche Modular	< 15% of CA15-3	%
CA19-9 concentration as determined by Roche Modular	< 15% of CA15-3	%
CA72-4 concentration as determined by Roche Modular	< 10% of CA15-3	%
CYFRA 21-1 concentration as determined by Roche Modular	Report Result	µg/ml
CEA concentration as determined by Roche Modular.	Report Result	µg/ml
Protein concentration as determined by Pierce BCA method	Report result	mg/ml
Bioburden	< 100 CFU/mI	Pass/Fail
Physical Appearance	Clear to opalescent colourless frozen liquid.	
Purity	Total measured contaminants are < 40% of the total CA15-3 concentration.	
Name:	Position:	
Signed:	Date:	

Part of **BBI Group**